EUVIMEDEUVIMED entdecken
Crossref

Utility of the C-Peptide/Insulin Molar Ratio for Distinguishing Type A Insulin Resistance Syndrome From Type 2 Diabetes

Seiji Nishikage iD, Yushi Hirota iD, Tomofumi Takayoshi iD, Kai Yoshimura iD, Takehito Takeuchi, Tetsushi Hamaguchi, Mariko Ueda, Akane Yamamoto iD, Kazuhiko Sakaguchi iD, Wataru Ogawa iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Seiji Nishikage und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, C-Peptide, Insulin Resistance, Insulin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Ministry of Health, Labour, and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Type A insulin resistance syndrome (IRS), characterized by impaired insulin receptor function due to variants of the insulin receptor gene, manifests as severe insulin-resistant diabetes. Differentiation of type A IRS from type 2 diabetes on the basis of hyperinsulinemia can be challenging. Given the association between insulin receptor dysfunction and reduced insulin clearance, we evaluated the potential of the circulating C-peptide reactivity (CPR)/immunoreactive insulin (IRI) molar ratio, a marker of insulin clearance, for distinguishing type A IRS from type 2 diabetes.

Methods

We retrospectively analyzed CPR and IRI levels measured during a 75-g oral glucose tolerance test (OGTT) in 18 individuals with type A IRS and 126 with type 2 diabetes. Receiver operating characteristic (ROC) curve analysis was performed to determine the diagnostic performance of the CPR/IRI molar ratio and IRI levels.

Results

IRI levels were significantly higher and the CPR/IRI molar ratio significantly lower in individuals with type A IRS compared with those with type 2 diabetes. The area under the ROC curve for the CPR/IRI molar ratio at baseline, 1 hour, and 2 hours after OGTT initiation was 0.997 (sensitivity 100%, specificity 99.2%), 0.999 (sensitivity 100%, specificity 97.6%), and 0.997 (sensitivity 100%, specificity 95.1%), respectively. The CPR/IRI molar ratio demonstrated robust diagnostic performance regardless of body mass index or hyperinsulinemia severity.

Conclusion

The CPR/IRI molar ratio, both at baseline and during OGTT, exhibited higher sensitivity and specificity than IRI levels alone for distinguishing type A IRS from type 2 diabetes. This ratio may serve as a reliable clinical marker for early and accurate diagnosis of type A IRS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2C-PeptideInsulin ResistanceInsulinMetabolic SyndromeHumansFemaleMaleMiddle AgedRetrospective StudiesDiagnosis, DifferentialGlucose Tolerance TestAdultAgedBiomarkersROC Curve

Stichwörter der Autor:innen

C-peptide reactivitydiagnostic markerhyperinsulinemiaimmunoreactive insulininsulin resistance syndromeoral glucose tolerance test

Substanzen

C-PeptideInsulinBiomarkers

Autor:innen und Institutionen

  • Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
  • Division of General Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.

ORCID-Profile: Seiji Nishikage, Yushi Hirota, Tomofumi Takayoshi, Kai Yoshimura, Akane Yamamoto, Kazuhiko Sakaguchi, Wataru Ogawa

Förderung

  • Ministry of Health, Labour, and Welfare

Zitieren

APA

Nishikage, S., Hirota, Y., Takayoshi, T., Yoshimura, K., Takeuchi, T., Hamaguchi, T., Ueda, M., Yamamoto, A., Sakaguchi, K., & Ogawa, W. (2025). Utility of the C-Peptide/Insulin Molar Ratio for Distinguishing Type A Insulin Resistance Syndrome From Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf043

Vancouver

Nishikage S, Hirota Y, Takayoshi T, Yoshimura K, Takeuchi T, Hamaguchi T, et al. Utility of the C-Peptide/Insulin Molar Ratio for Distinguishing Type A Insulin Resistance Syndrome From Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf043

BibTeX
@article{Nishikage2025,
  author = {Nishikage, Seiji and Hirota, Yushi and Takayoshi, Tomofumi and Yoshimura, Kai and Takeuchi, Takehito and Hamaguchi, Tetsushi and Ueda, Mariko and Yamamoto, Akane and Sakaguchi, Kazuhiko and Ogawa, Wataru},
  title = {Utility of the C-Peptide/Insulin Molar Ratio for Distinguishing Type A Insulin Resistance Syndrome From Type 2 Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf043}
}
Kostenlos starten →